ASCA101 combi-therapy (Oncology)
| Program | Indication | Combination | Pre-clinical | Phase I | Phase II | Phase III | |
|---|---|---|---|---|---|---|---|
 ASCA101 |
Ovarian cancer | BRCA wild-type / HRP | PARP inhibitor | ||||
| PARPi tolerance | |||||||
| Pt refractory | |||||||
| Breast cancer | TNBC | ||||||
| Prostate cancer | |||||||
| Liver cancer | TKI resistance | VEGF inhibitor | |||||
| Colon cancer | ICI |